Analysis Tools
reproductive system
 |
• at P70, no PLZF+ spermatogonial stem cells (SSCs) are detected in the seminiferous tubules of tamoxifen-treated mice
• at P14, no pachytene spermatocytes are detected in the tubules of tamoxifen-treated mice
|
|
|
• at P14 and P70, the number of TUNEL+ apoptotic spermatocytes in the seminiferous tubules of tamoxifen-treated mice is significantly higher than in control males
|
small testis
(
J:324159
)
|
|
• at P70, tamoxifen-treated mice show a significantly smaller testis size than control males
|
|
|
• at P70, testis weight in tamoxifen-treated mice is 80% of that in control males
|
|
|
• tamoxifen-treated males exhibit early spermatogenic cells loss and apoptosis
|
|
|
• at P14, no pachytene spermatocytes are detected in the seminiferous tubules of tamoxifen-treated mice
• at P70, chromosome spreads from tamoxifen-treated testes show a significant decrease in leptotene, zygotene and pachytene spermatocytes with a concomitant increase in diplotene and metaphase I cells relative to control testes
• at P70, % of pachytene spermatocytes is significantly lower than in control testes (12.57% versus 41.37%) whereas % of diplotene spermatocytes is significantly increased (82.74% versus 48.83%)
|
|
|
• at P14, no meiotic cells are found in the testes of tamoxifen-treated mice; only mitotic cells are observed
• no SYCP3+ or gammaH2AX+ cells are observed in the seminiferous tubules of tamoxifen-treated mice at P14
• at P70, chromosome spreads from tamoxifen-treated testes show meiosis defects, including a significant reduction in zygotene and pachytene spermatocytes, defective double-strand DNA repair, and a significant decrease in MLH1 foci in pachytene spermatocytes indicating reduced crossover formation
|
cellular
|
|
• at P14, no pachytene spermatocytes are detected in the seminiferous tubules of tamoxifen-treated mice
• at P70, chromosome spreads from tamoxifen-treated testes show a significant decrease in leptotene, zygotene and pachytene spermatocytes with a concomitant increase in diplotene and metaphase I cells relative to control testes
• at P70, % of pachytene spermatocytes is significantly lower than in control testes (12.57% versus 41.37%) whereas % of diplotene spermatocytes is significantly increased (82.74% versus 48.83%)
|
|
|
• at P70, no PLZF+ spermatogonial stem cells (SSCs) are detected in the seminiferous tubules of tamoxifen-treated mice
• at P14, no pachytene spermatocytes are detected in the tubules of tamoxifen-treated mice
|
|
|
• at P14, no meiotic cells are found in the testes of tamoxifen-treated mice; only mitotic cells are observed
• no SYCP3+ or gammaH2AX+ cells are observed in the seminiferous tubules of tamoxifen-treated mice at P14
• at P70, chromosome spreads from tamoxifen-treated testes show meiosis defects, including a significant reduction in zygotene and pachytene spermatocytes, defective double-strand DNA repair, and a significant decrease in MLH1 foci in pachytene spermatocytes indicating reduced crossover formation
|
|
|
• at P14 and P70, the number of TUNEL+ apoptotic spermatocytes in the seminiferous tubules of tamoxifen-treated mice is significantly higher than in control males
|
|
|
• at P70, chromosome spreads from tamoxifen-treated testes show abnormal accumulation of gammaH2AX foci on the axes of autosomal chromosomes as well as a significant increase of DMC1 foci in pachytene spermatocytes, indicating an increased incidence of unrepaired DNA breaks
|
homeostasis/metabolism
|
|
• at P70, chromosome spreads from tamoxifen-treated testes show abnormal accumulation of gammaH2AX foci on the axes of autosomal chromosomes as well as a significant increase of DMC1 foci in pachytene spermatocytes, indicating an increased incidence of unrepaired DNA breaks
|
endocrine/exocrine glands
small testis
(
J:324159
)
|
|
• at P70, tamoxifen-treated mice show a significantly smaller testis size than control males
|
|
|
• at P70, testis weight in tamoxifen-treated mice is 80% of that in control males
|
